RIQAS Inter-Laboratory Group Report
RIQAS Inter-Laboratory Group Report
A unique group reporting facility is available allowing laboratory groups or chains to effectively monitor the performance of satellite sites.
All laboratories within a group will receive their RIQAS sample packs, analyse the samples, return results to RIQAS and receive their individual RIQAS reports as normal. In addition to this a separate group report will be sent to the group manager or supervisor allowing relative performance of all laboratories within the group to be assessed.
RIQAS EQA Reports
RIQAS End-of-Cycle Report
RIQAS End-of-Cycle reports are sent to all participants who receive the standard report. Therefore, participants who are enrolled in RIQAS Urinalysis, RIQAS Urine Toxicology and RIQAS Serology programmes will not receive an End-of-Cycle report.
The RIQAS End-of-Cycle report provides laboratories with a complete summary of their External Quality Assessment performance. Performance is also compared to that of the previous cycle providing an indication of progress and improvement over time. Data is presented in both written and graphical format allowing a visual assessment of overall performance.
The RIQAS End-of-Cycle report is split into 3 sub-sections. These sub-sections are designed to allow performance assessment at a glance.
RIQAS EQA Reports
RIQAS End-of-Cycle Report Features
The Parameter Cycle Summary section provides an overview of the results returned for each sample in the cycle. The text section summarises the laboratory’s result compared to the Mean for Comparison. Laboratory performance for the current cycle is also compared to that of the previous cycle. A variety of charts including Levey-Jennings, Target Score, % Deviation by sample and % Deviation by concentration are also presented allowing a visual assessment of laboratory performance over the cycle.
A certificate of performance is provided listing all parameters, for which the laboratory achieved an acceptable level of performance (Average Absolute SDI <2). Although the End-of-Cycle Report is issued for all registered parameters, the certificate of performance will only be available for parameters where results for at least 50% of samples in the cycle have been returned.
RIQAS Standard Report
There are a variety of RIQAS reports designed to enable quick and easy identification of any trends or test system issues. The standard quantitative report is provided in a user-friendly, one page per parameter format allowing a visual, at-a-glance assessment of performance. The standard quantitative report is split into several easy to interpret subsections each designed to save valuable laboratory time.
You can explore each of the report sections using the table below. Don’t forget, to enlarge the image, simply click on it.
RIQAS EQA Reports
RIQAS Reports Features
The text section provides a statistical breakdown of results by all methods, your method and instrument group. The Mean, CV% and Uncertainty or Measurement is presented for each comparison group.
Your laboratory’s result is compared to the Mean for Comparison (usually the instrument group Mean). Also included are the RIQAS performance indicators; SDI, Target Score and %Deviation.
Acceptable performance criteria:
- SDI <2
- Target Score >50
- %Deviation
The defined acceptable limits default to the RIQAS TDPA values but may be based on CLIA, biological variation or country specific limits.
Performance goals based on Biological Variation are also stated within the text section for information purposes.
The histogram chart provides an overview of how your laboratory’s result compares to the all method group, your method group and your instrument group. Your result is represented by a black triangle; the closer to the centre the better.
The chart is intended to provide a quick visualisation of performance compared to other method groups and can be used to identify any potential bias.
The Levey-Jennings chart plots the last 20 SDI’s and is extremely useful for monitoring EQA performance over time, allowing quick and easy identification of any trends or bias. The chart is colour coded making interpretation simple and easy; results that fall in the white area are excellent and those in the red area unacceptable.
The Target Score (TS) chart is a unique chart which displays your laboratory’s last 20 target scores delivering an instant, visual indication of performance. The TS chart is conveniently colour coded for even easier performance assessment, a TS >50 is acceptable. The TS is a numerical index relating your %Deviation from the mean to a Target Deviation for Performance Assessment (TDPA).
The %Deviation by sample chart displays the %Deviation for the last 20 EQA samples enabling identification of trends and shifts in performance. Similar to the other charts on the RIQAS report, the %Deviation by sample chart is shaded to indicate the limit of acceptable performance. A black dot within the white section of the chart will represent results with a %Deviation within your acceptable limits of performance; a black dot within the red section of the chart will represent results with a %Deviation outside your acceptable limits of performance. %Deviations are not influenced by the performance of your peers, as seen with the standard deviation index (SDI) and therefore is a better indicator of individual performance.
The %Deviation by concentration chart enables easy detection of possible concentration related biases. Unlike the other charts provided on the report, the %Deviation by concentration chart displays the concentration range of the previous 20 samples along the bottom of the chart.
Using this scale along with the percentage deviation, you are provided with a rapid assessment of your %Deviation in relation to the concentration of the:
• Current sample (represented by a square)
• Your 19 previous results (represented by circles)
This chart provides an easy interpretation of potential positive or negative biases at high or low concentrations, or whether a particular sample is a random outlier.
Located at the back of the standard quantitative report, our quick reference summary page details the performance for each registered parameter in the programme.
Within the performance column, RIQAS provides an effortless method of assessing the performance of each parameter within the sample distribution. When a red triangle appears next to the parameter, this indicates that all performance indicators (SDI, TS and %DEV) have exceeded the performance criteria.
The performance indicator limits for each parameter are exceeded when your result produces:
• An SDI greater than +/- 2 standard deviations.
• A Target Score less than 50 (only when Target Scoring is available)
• A %Deviation greater than your set acceptable limits of performance.
A summary CSV file is available on request to all participating laboratories. The report provides a summary of all statistics, acceptable limits and performance indicators as a .csv file for each sample in the cycle.
A retrospective statistics summary is also available, four weeks after the final submission date for parameters where a result was not submitted on time.
RIQAS Parameters List
RIQAS is the largest international External Quality Assessment (EQA)/ Proficiency Testing (PT) scheme, there are currently more than 55,000 participants in 134 countries. World renowned for reducing the number of individual programmes required by even the most demanding laboratories, RIQAS covers 360 parameters across 36 flexible multi-parameter programmes. Effective consolidation in this way will not only deliver real cost savings but free up storage space and ultimately reduce the time spent preparing multiple samples at each survey.
RIQAS Parameter List
1-25-(OH)₂-Vitamin D
17-OH-Progesterone
25-OH-Vitamin D
5-HIAA
α-1-Acid Glycoprotein
α-1-Antitryspin
α-2-Macroglobulin
ACE (Angiotensin Converting Enzyme)
Acid Phosphatase (Prostatic)
Acid Phosphatase (Total)
ACR
ACTH
AFP
Albumin
Aldosterone
Alkaline Phosphatase
ALT
ALT (ALAT)
Amikacin
Ammonia
Amylase (Pancreatic)
Amylase (Total)
Androstenedione
Anti Streptolysin O (ASO)
Anti-CMV
Anti-CMV IgG
Anti-CMV IgM
Anti-EBNA IgG
Anti-EBV VCA IgG
Anti-EBV VCA IgM
Anti-HAV IGM*
Anti-HAV (Total)*
Anti-HBc
Anti-HBc IgM*
Anti-HBe (Total)*
Anti-HBs (Total)*
Anti-HCV
Anti-HIV-1
Anti-HIV-1 & 2 Combined
Anti-HIV-2
Anti-HSV- 1 & 2 IgG Combined
Anti-HSV- 1 & 2 IgM Combined
Anti-HSV1 IgG
Anti-HSV1 IgM
Anti-HSV2 IgG
Anti-HSV2 IgM
Anti-HTLV-1 & 2 Combined
Anti-HTLV-I
Anti-HTLV-II
Anti-Measles IgG*
Antimicrobial Susceptibility Testing
Anti-Müllerian Hormone (AMH)
Anti-Mumps IgG*
Anti-Rubella IgG
Anti-Rubella IgM
Anti-SARS-COV2 IgG
Anti-SARS-COV2 IgM
Anti-SARS-COV2 Total
Anti-TG
Antithrombin III
Anti-Toxoplasma IgG
Anti-Toxoplasma IgM
Anti-TPO
Anti-TSH Receptor (TRAb)
Anti-VZV IgG*
Apolipoprotein AI
Apolipoprotein B
aPTT
AST
AST (ASAT)
β-2-Microglobulin
Benzoylecgonine
Bicarbonate
Bile Acids
Bilirubin (Direct)
Bilirubin (Total)
Blood
BNP
Buprenorphine
CA15-3
CA19-9
CA125
Caffeine
Calcitonin
Calcium
Calcium, Adjusted
Calcium (Ionised)
Cannabinoids (THC)
Carbamazepine
Carboxyhaemoglobin (COHb / HbCO)
CEA
Ceruloplasmin
Chloride
Cholesterol (Total)
Cholinesterase
Ciclosporin
CK, Total
CK-MB (Activity)
CK-MB (Mass)
CK NAC
CO2, Total
Complement C₃
Complement C₄
Conductivity
Copper
Cortisol
Cotinine
C-Peptide
C-Reactive Protein (CRP)
Creatinine
CYFRA 21-1 (Cytokeratin 19)
D-3-Hydroxybutyrate
d-Amphetamine
D-Dimer*
Deoxyhaemoglobin (HHb)
DHEA Unconjugated
DHEA-Sulphate
Digoxin
d-Methamphetamine
Dopamine
EDDP
Epinephrine
ESR
Estriol Total
Ethanol
Ethosuximide
Everolimus
Factor II
Factor IX
Factor V
Factor VII
Factor VIII
Factor X
Factor XI
Factor XII
Ferritin
Fibrinogen
Folate
Free Morphine
free β-hCG
Fructosamine
FSH
γ-GT
Galactose
Gastrin
Gentamicin
Growth Hormone (GH)
GLDH
Glucose
Haematocrit (HCT)
Haemoglobin (Hb)
Total Haemoglobin (tHb)
Haemolysis
Haptoglobin
HbA1c
HBsAG
HBDH
hCG
HDL-Cholesterol
Homocysteine
hsCRP
Icteric
IgA
IgE
IGF-1
IgG
IgM
Inhibin A
Insulin
Interferon gamma (INF-Y)*
Interleukin – 1 alpha (IL-1α)*
Interleukin – 1 beta (IL-1β)*
Interleukin – 10 (IL-10)*
Interleukin – 2 (IL-2)*
Interleukin – 4 (IL-4)*
Interleukin – 6 (IL-6)
Interleukin – 8 (IL-8)*
Iron
Kappa Light Chain (Free)
Kappa Light Chain (Total)
Ketones
Lactate
Lambda Light Chain (Free)
Lambda Light Chain (Total)
LD (LDH)
LDL-Cholesterol
Lead
Leucocytes
Lipase
Lipoprotein (a)
Lithium
Lorazepam
LSD
Luteinising Hormone (LH)
Magnesium
MDMA
Mean Cell Haemoglobin (MCH)
Mean Cell Haemoglobin Concentration (MCHC)
Mean Cell Volume (MCV)
Mean Platelet Volume (MPV)
Metanephrine
Methadone
Methaemoglobin (MetHb)
Methotrexate
Monocyte Chemoattractant Protein -1 (MCP-1)*
Myoglobin
NEFA
Nitrite
Non-HDL Cholesterol
Norepinephrine
Normetanephrine
Norpropoxyphene
Nortriptyline
NT proBNP
Oestradiol
Osmolality
Osteocalcin
Oxalate
Oxazepam
Oxygen Content (O2CT)
Oxygen Saturation (sO2 / Vol O2)
Oxyhaemoglobin (O2Hb / HbO2)
P24*
PAPP-A
Paracetamol (Acetaminophen)
pCO₂
pH
Phencyclidine
Phenobarbital
Phenytoin
Phosphate (Inorganic)
Plasma Renin Activity
Plasminogen
Plateletcrit (PCT)
Platelets (PLT)
pO₂
Potassium
Prealbumin (Transthyretin)
Primidone
Procalcitonin
Progesterone
Prolactin
Protein (Total)
Protein C
Protein S
PSA (Free)
PSA (Total)
PT (Including INR)
PTH
Red Blood Bell Count (RBC)
Red Cell Distribution Width (RDW)
Renin (Direct Concentration)
Retinol Binding Protein
Rheumatoid Factor
Salicylic Acid
Secobarbital
SHBG
Sirolimus
Sodium
Specific Gravity
Syphilis
T₃ (Free)
T₃ (Total)
T₄ (Free)
T₄ (Total)
Tacrolimus
Testosterone (Free)*
Testosterone (Total)
Theophylline
Thyroglobulin
TIBC
Tobramycin
Total hCG
Transferrin
Triglycerides
Troponin I
Troponin T
TSH
TT
Tumor Necrosis Factor alpha (TNF-a)*
UIBC
Unconjugated Oestriol
Urea
Uric Acid
Urobilinogen
Valproic Acid
Vancomycin
Vascular Endothelial Growth Factor (VEGF)*
Vitamin B₁₂
VMA
Total White Blood Cell Count (WBC)
Zinc
RIQAS – Randox International Quality Assessment Scheme


The World’s Largest External Quality Assessment Scheme
Uniquely connecting you with 45,000 laboratory participants across 32 flexible yet comprehensive programmes, RIQAS is the world’s largest external quality assessment (EQA) scheme. Access to maximised peer groups ensures availability of comparison data for a wide range of instruments and methods, ultimately increasing confidence in test system reliability. The added benefit of frequent analysis, user-friendly reports, multi-instrument reports and consolidated programmes makes a cost-effective, high quality EQA solution for any laboratory.
Benefits of RIQAS
Consolidation
Comprised of over 360 parameters in 32 comprehensive programmes, RIQAS streamlines EQA by significantly reducing the number of individual programmes required.
User-friendly reports
RIQAS presents reports in a simple one page per parameter format for at-a-glance performance assessment, including Levey-Jennings charts, Histograms, % Deviation charts, and more; providing a visual representation of laboratory performance, all within 24-72 hours of the submission deadline.
Frequency
Frequent analysis coupled with our rapid report turnaround will allow labs to pinpoint when an error occurred and implement any corrective actions necessary.
Flexibility
With 32 flexible EQA programmes available, RIQAS has something to suit every lab. Reduced parameter and report options ensures suitability for laboratories of every size and budget.
The ability to register up to 5 instruments per programme at no extra cost will ultimately save money facilitating comparative performance assessment.
Accreditation
Being part of a reputable External Quality Assessment scheme like RIQAS is highly encouraged by international and national regulatory bodies and will help your laboratory meet ISO 15189:2012 accreditation requirements:
“the laboratory shall participate in inter-laboratory comparisons such as those organised by external quality assessment schemes…”, “EQA should, as far as possible, cover the entire range of tests, and the entire examination process, from sample reception, preparation and analysis to interpretation and reporting.”
RIQAS systems and procedures are accredited to ISO 17043:2010 ‘Conformity Assessment – General Requirements for Proficiency Testing’ ensuring a high quality programme that is fit for purpose and will assist laboratories in meeting and maintaining ISO 15189:2012 standards.
In addition to ISO 17043:2010, RIQAS is recognised by the UK National Quality Assurance Advisory Panel (NQAAP) for Clinical Pathology and the Joint Working Group on Quality Assurance (JWG QA).
Learn More
To learn more or to get signed up, fill in the contact form below.
Randox Quality Control – More than EQA
Did you know that Randox is the company behind the RIQAS EQA scheme? RIQAS (Randox International Quality Assessment Scheme) is just one area of our comprehensive Quality Control portfolio. As such it is our resolution this New Year to introduce Randox as the brains behind RIQAS and show you that we are more than just an EQA provider by sharing our passion for laboratory QC.
Who are Randox Quality Control?
At Randox we believe in producing high quality material that can help streamline procedures, whilst saving time and money for laboratories of all sizes and budgets. With our extensive product offering comprising third party QC sera, interlaboratory data management software and calibration verification products, you can be sure that our complete QC solutions will provide you with a comprehensive overview of laboratory performance.
Seeing the complete picture with Randox QC
Acusera QC sera
As one of the largest manufacturers of true third party, commutable controls we deliver high quality, cost effective quality control solutions designed to accurately assess instrument performance and provide confidence in patient test results.
Acusera 24.7 interlaboratory data management
Acusera 24.7 enables you to drive for more accurate results by helping you to monitor and interpret QC data. With access to an impressive range of features, including the automatic calculation of Measurement Uncertainty, Total Error and Sigma Metrics, Acusera 24.7 ensures analytical quality.
RIQAS EQA Scheme
RIQAS is employed by more than 45,000 laboratory participants in 124 countries. With frequent reporting you will identify errors sooner ultimately reducing the need to carry out preventable, expensive retests on a large volume of patient samples.
Acusera Calibration Verification sera and software
The Acusera linearity sets cover a wide range of clinical testing including; cardiac markers, therapeutic drugs and proteins. Designed with convenience in mind, the range ultimately helps you to meet CLIA requirements for calibration verification and the assessment of linearity.
Randox QC Resources Hub
Beyond selling laboratory QC we are also passionate about education, offering a range of educational guides, seminars and webinars, with more to come throughout 2017. Check out our QC resources hub for our current educational material and let us know what educational material you would like to see.
For more information, or to request a visit from one of our QC Consultants, contact us via acusera@randox.com.
CYFRA 21-1 External Quality Assessment
The RIQAS CYFRA 21-1 EQA programme is designed to cover the analysis of CYFRA 21-1 in clinical laboratories when monitoring the response to treatment of cancers such as non-small cell lung carcinoma, cervical, breast and bladder cancer.
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Not accredited to ISO/IEC 17043
Cat No | Kit Size | Frequency | Cycle Start | Parameters | |
---|---|---|---|---|---|
RQ9175 | 12 x 1ml | Monthly | March | 1 | |
Parameter
- CYFRA 21-1 (Cytokeratin 19)
Please note, product availability may vary country to country.
Related Products
Anti-TSH Receptor External Quality Assessment
The RIQAS Anti-TSH Receptor EQA programme is designed to cover the analysis of Anti-TSH Receptor in clinical laboratories when thyroid dysfunction is suspected.
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Not accredited to ISO/IEC 17043
Cat No | Kit Size | Frequency | Cycle Start | Parameters | |
---|---|---|---|---|---|
RQ9174 | 12 x 1ml | Monthly | March | 1 | |
Parameter
- Anti-TSH Receptor (TRAb)
Please note, product availability may vary country to country.
Related Products
Immunosuppressant External Quality Assessment
The RIQAS Immunosuppressant EQA programme has been designed to cover the analysis of Immunosuppressants in clinical laboratories. Immunosuppressants are primarily used after transplant operations to prevent the host body from rejecting donor organs.
- Lyophilised samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
- LC/MS reference values provided enabling participants to compare results to an accurately assigned value
Not accredited to ISO/IEC 17043
Cat No | Kit Size | Frequency | Cycle Start | Parameters | |
---|---|---|---|---|---|
RQ9159 | 12 x 2ml | Monthly | March | 4 | |
Parameters
- Cyclosporin
- Everolimus
- Sirolimus
- Tacrolimus
Please note, product availability may vary country to country.
Related Products
Sweat Testing External Quality Assessment
The RIQAS Sweat Testing EQA programme has been designed to cover the analysis of Sweat Testing in clinical laboratories measuring the concentration of Chloride and Conductivity in sweat, used in the testing of Cystic Fibrosis (CF).
- Liquid ready-to-use samples
- Monthly reporting
- Testing covers the full range of clinically relevant decision levels
- Submit results and view reports online via RIQAS.net
- 12 month subscription
Not accredited to ISO/IEC 17043
Cat No | Kit Size | Frequency | Cycle Start | Parameters | |
---|---|---|---|---|---|
RQ9173 | 12 x 2ml | Monthly | March | 2 | |
Parameter
- Chloride
- Conductivity
Please note, product availability may vary country to country.